Cat. No.: HY-B0356

Ciprofloxacin

(Synonyms: Bay-09867)

57 Cited Publications

Customer Review

Based on 57 publication(s) in Google Scholar

Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 85721-33-1
Formula: C₁₇H₁₈FN₃O₃
Molecular Weight:331.34

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ciprofloxacin Chemical Structure

CAS No.: 85721-33-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (57)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Quinolone

All Topoisomerase Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	135 μM Compound: 1	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
A-431	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A-431	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A549	IC₅₀	280 μM Compound: 1	Antitumor activity against human A549 cells after 5 days by MTT assay Antitumor activity against human A549 cells after 5 days by MTT assay	[PMID: 19595598]
A549	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
B-cell	IC₅₀	123 μM Compound: ciprofloxacin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
C8166	EC₅₀	100 μM Compound: CPX, ciprofloxacin	In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells. In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.	[PMID: 11020296]
CAPAN-1	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
CHO	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against CHO cells assessed as reduction in cell viability Cytotoxicity against CHO cells assessed as reduction in cell viability	[PMID: 30660827]
CHO	CC₅₀	512 μM Compound: CPFX	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
CHO	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
CT26	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	202 μM Compound: 1	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
EJ	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
HaCaT	IC₅₀	222.1 μM Compound: CP	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HBL-100	IC₅₀	10.28 μM Compound: C; Cip	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34319100]
HEK-293T	CC₅₀	>60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
HeLa	IC₅₀	120 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	290 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	270 μM Compound: 1	Inhibition of human HeLa cell proliferation Inhibition of human HeLa cell proliferation	[PMID: 19595598]
HeLa	IC₅₀	800 μM Compound: 1	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
HeLa	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay	[PMID: 27018907]
HeLa	EC₅₀	0.03 μM Compound: Ciprofloxacin	Inhibitory activity against HeLa cell Topoisomerase II Inhibitory activity against HeLa cell Topoisomerase II	10.1016/0960-894X(95)00160-U
Hep 3B2	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HEp-2	CC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against Hep2 cell line Cytotoxicity against Hep2 cell line	[PMID: 16337789]
HEp-2	CC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep2 laryngeal carcinoma cell line Cytotoxicity against human Hep2 laryngeal carcinoma cell line	[PMID: 16337791]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HepG2	IC₅₀	37.47 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in HepG2 cell line Cytotoxicity was determined for the compound in HepG2 cell line	[PMID: 14980680]
HepG2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay	[PMID: 21855181]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay	[PMID: 27499455]
HepG2	IC₅₀	27 μM Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 28237557]
HepG2	CC₅₀	138.6 μg/mL Compound: CPX	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay	[PMID: 30067360]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay	[PMID: 35231579]
HepG2	IC₅₀	>170 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay	[PMID: 38157595]
HL-60	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability Cytotoxicity against human HL60 cells assessed as reduction in cell viability	[PMID: 30660827]
HL-60	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
K562	IC₅₀	>150 μM Compound: 1	Inhibition of human K562 cell proliferation by sulphorodhamine B assay Inhibition of human K562 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
KB	IC₅₀	160 μM Compound: 1	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
KB	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
L02	IC₅₀	12.23 μM Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	4.05 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	>64 μg/mL Compound: Cip	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38096652]
L1210	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability	[PMID: 30660827]
L1210	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against mouse L1210 cells by MTT assay Antiproliferative activity against mouse L1210 cells by MTT assay	[PMID: 30660827]
L1210	IC₅₀	>150 μM Compound: CFX	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
LoVo	IC₅₀	89 μM Compound: 1	Antitumor activity against human LoVo cells after 5 days by MTT assay Antitumor activity against human LoVo cells after 5 days by MTT assay	[PMID: 19595598]
MC3T3-E1	IC₅₀	120 μM Compound: 1	Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs	[PMID: 19595598]
MCF-10A	IC₅₀	>300 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	[PMID: 24513049]
MCF7	IC₅₀	199 μM Compound: 1	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	476 μM Compound: 1	Antitumor activity against human MCF7 cells after 5 days by MTT assay Antitumor activity against human MCF7 cells after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	76 μM Compound: 1	Inhibition of human MCF7 cell proliferation after 5 days by MTT assay Inhibition of human MCF7 cell proliferation after 5 days by MTT assay	[PMID: 19595598]
MCF7	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
MCF7	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MCF7	IC₅₀	8.85 μM Compound: C; Cip	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MG-63	IC₅₀	150 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	160 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	480 μM Compound: 1	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	181 μM Compound: Ciprofloxacin	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 24206766]
MRC5	IC₅₀	53.4 μg/mL Compound: CPF	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31431360]
MT4	CC₅₀	60 μM Compound: Ciprofloxacin	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 10397494]
NCI-H460	IC₅₀	60 μM Compound: 1	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
NIH3T3	IC₅₀	>1000 μM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	>200 μM Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay	[PMID: 23711920]
NIH3T3	IC₅₀	305.77 μg/mL Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	>400 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PBMC	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human PBMC measured after overnight incubation by MTT assay Cytotoxicity against human PBMC measured after overnight incubation by MTT assay	[PMID: 21855181]
PC-3	IC₅₀	143 μM Compound: 1	Antitumor activity against human PC3 cells after 5 days by MTT assay Antitumor activity against human PC3 cells after 5 days by MTT assay	[PMID: 19595598]
PC-3	IC₅₀	101.4 μM Compound: CP	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SH-SY5Y	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay	[PMID: 21855181]
SK-MEL	IC₅₀	196 μM Compound: 1	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SK-MEL3	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SMMC-7721	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Splenocyte	IC₅₀	>40 μM Compound: CIPRO	Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method	[PMID: 19908867]
SW480	IC₅₀	128 μM Compound: 1	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]
SW480	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	160.4 μM Compound: CP	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW480	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SW-620	IC₅₀	200.4 μM Compound: CP	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
THP-1	IC₅₀	60.5 μM Compound: Ciprofloxacin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
U-373MG ATCC	IC₅₀	96 μM Compound: 1	Antitumor activity against human U373MG cells after 5 days by MTT assay Antitumor activity against human U373MG cells after 5 days by MTT assay	[PMID: 19595598]
V79	IC₅₀	380 μg/mL Compound: 29a	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	[PMID: 1469702]
V79	IC₅₀	>1000 μM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
V79	IC₅₀	>320 μg/mL Compound: 22	Clonogenic cytotoxicity against Chinese hamster V-79 cells Clonogenic cytotoxicity against Chinese hamster V-79 cells	[PMID: 7473575]
V79	IC₅₀	>200 μg/mL Compound: 21 Ciprofloxacin	Clonogenic cytotoxicity against Hamster V-79 cells Clonogenic cytotoxicity against Hamster V-79 cells	[PMID: 8145222]
V79-4	IC₅₀	58.55 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in V79-4 cell line Cytotoxicity was determined for the compound in V79-4 cell line	[PMID: 14980680]
Vero	IC₅₀	>188.5 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	CC₅₀	600.8 μM Compound: CPFX	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	IC₅₀	192 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24206766]
Vero	CC₅₀	128 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	512 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
Vero	CC₅₀	128 μg/mL Compound: Ciprofloxacin	Cytotoxicity in African green monkey Vero cells Cytotoxicity in African green monkey Vero cells	[PMID: 31358466]
WI-38	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]

In Vitro

Ciprofloxacin (Bay-09867) (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase^[1].
Ciprofloxacin (Bay-09867) shows potent activity against Y. pestis and B. anthracis with MIC₉₀ of 0.03 μg/mL and 0.12 μg/mL, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

Tendon cells
Concentration:

5, 10, 20 and 50 μg/mL
Incubation Time:

24 hours
Result:

Decreased the cellularity of tendon cells.

Apoptosis Analysis^[1]

Cell Line:

Tendon cells
Concentration:

50 μg/mL
Incubation Time:

24 hours
Result:

Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.

Western Blot Analysis^[1]

Cell Line:

Tendon cells
Concentration:

50 μg/mL
Incubation Time:

0, 6, 12, 17 and 24 hours
Result:

Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.

In Vivo

Ciprofloxacin (Bay-09867) (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague^[3].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall^[4].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c mice^[3]
Dosage:

30 mg/kg
Administration:

Intraperitoneal injection; for 24 hours
Result:

Reduced the lung bacterial load in murine model of pneumonic plague.

Animal Model:

C57BL/6J mice^[4]
Dosage:

100 mg/kg
Administration:

Oral gavage; daily, for 4 weeks
Result:

Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.

Animal Model:

C57BL/6J mice^[4]
Dosage:

100 mg/kg
Administration:

Oral gavage; daily, for 4 weeks
Result:

Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.

Chemical Information

CAS No. 85721-33-1
Appearance Solid
Molecular Weight 331.34
Formula C₁₇H₁₈FN₃O₃
Color White to off-white
SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Synonyms

Bay-09867
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (57)

All Bio/Physico-chemical AssayMicrobiological AssayOthers2D/3D Cell Culture and DifferentiationFlow Cytometry

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Nature

Gut microbiota carcinogen metabolism causes distal tissue tumours. [Abstract]

2024 Aug;632(8027):1137-1144. PMID: 39085612
Mater Today

2026 Apr 7;96:103326.
Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
Adv Sci (Weinh)

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]

2020 Jul 21;7(17):2001374. PMID: 32995131
Chem Eng J

2025 May 1.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

The number of surviving bacteria after 24 h of treatment with free Ciprofloxacin monohydrochloride or Ciprofloxacin monohydrochloride-loaded liposomes at 658 a 3 μg/mL of Ciprofloxacin monohydrochloride concentration.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

The CI values for 660 antibacterial efficacy of blank liposomes and Ciprofloxacin monohydrochloride.
Water Res

Variable cyanobacterial death modes caused by ciprofloxacin in the aquatic environment: Prioritizing antibiotic-photosynthetic protein interactions for risk assessment. [Abstract]

2024 Nov 29:271:122885. PMID: 39642793

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 0-7 days) caused concentration-dependent damage in M. aeruginosa cells.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 3 or 7 days) increased the release and decreased the biosynthesis of MC-LR in M. aeruginosa cells.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 8 μg/L, 1 day) enriched gene ontology terms related to PSI in M. aeruginosa cells.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 21 days) induced continuous cell lysis, with maximum lytic rates of ∼70% compared to the initial cell density.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 1, 3, 5, or 7 days) induced cell death in M. aeruginosa.
Water Res

Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. [Abstract]

2023 Jul 15:240:120110. PMID: 37247434
EBioMedicine

A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]

2022 Apr;78:103943. PMID: 35306337
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Genome Biol

Caloric restriction remodels the hepatic chromatin landscape and bile acid metabolism by modulating the gut microbiota. [Abstract]

2023 Apr 30;24(1):98. PMID: 37122023
NPJ Biofilms Microbiomes

Gut microbiota dysbiosis-mediated ceramides elevation contributes to corticosterone-induced depression by impairing mitochondrial function. [Abstract]

2024 Oct 28;10(1):111. PMID: 39468065
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299
Food Res Int

Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]

2026 Aug 31:238:119421. PMID: 42215089
Arch Pharm Res

Cell membrane chromatography relative competitive method for the accurate determination of relative KD values of drug-receptor interactions. [Abstract]

2025 Jan;48(1):102-114. PMID: 39658753
Emerg Contam

2026 Feb 23.
J Med Chem

Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase. [Abstract]

2025 Dec 11;68(23):25274-25289. PMID: 41277442
J Agric Food Chem

Discovery of DNA Gyrase as a Promising Target against Phytopathogenic Bacteria. [Abstract]

2025 Dec 23. PMID: 41436099
Anal Chim Acta

A natural fluorescent protein for ciprofloxacin sensing and mechanism study using molecular docking and circular dichroism. [Abstract]

2022 Aug 15:1221:340082. PMID: 35934392
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Colloids Surf A Physicochem Eng Asp

2025 Dec 26;734:139401.
Virulence

Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]

2024 Dec;15(1):2415952. PMID: 39390774
Arab J Chem

2024 May, 17, 5, 105745.
PLoS Pathog

Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]

2024 Dec 31;20(12):e1012783. PMID: 39739989
ACS Appl Polym Mater

2023 Aug 29.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Representative TEM images of blank micelles (BM) and Ciprofloxacin monohydrochloride-loaded micelles (CM) formulated in 1× PBS at pH 7.4.

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Cumulative ciprofloxacin release from Ciprofloxacin monohydrochloride-loaded micelles over 72 h with an inset of the release over the first 12 h at pH 4.4 (red) and pH 7.4 (gray).

Ciprofloxacin purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Cumulative Ciprofloxacin monohydrochloride release at 12 and 72 h.
Molecules

Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. [Abstract]

2023 Jun 8;28(12):4628. PMID: 37375183
Int J Antimicrob Agents

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]

2018 Aug;52(2):269-271. PMID: 29559273
Antimicrob Agents Chemother

Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. [Abstract]

2026 Apr;70(4):e0170625. PMID: 41810969
Antimicrob Agents Chemother

An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]

2025 May 23:e0024925. PMID: 40407337
Front Microbiol

Enrofloxacin Promotes Plasmid-Mediated Conjugation Transfer of Fluoroquinolone-Resistance Gene qnrS. [Abstract]

2022 Feb 16:12:773664. PMID: 35250901
Appl Microbiol Biotechnol

Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA. [Abstract]

2022 Apr;106(7):2689-2702. PMID: 35338386
iScience

Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts. [Abstract]

2023 Oct 7;26(11):108158. PMID: 37915596
Microbiol Spectr

Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]

2025 May 19:e0307424. PMID: 40387379
Microbiol Spectr

Phenotypic and Genotypic Characterization of Multidrug-Resistant Enterobacter hormaechei Carrying qnrS Gene Isolated from Chicken Feed in China. [Abstract]

2022 Apr 25:e0251821. PMID: 35467399
Microbiol Spectr

The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]

2022 Feb 23;10(1):e0099121. PMID: 35019708
Cardiovasc Toxicol

Ciprofloxacin Accelerates Angiotensin-II-Induced Vascular Smooth Muscle Cells Senescence Through Modulating AMPK/ROS pathway in Aortic Aneurysm and Dissection. [Abstract]

2024 Sep;24(9):889-903. PMID: 39138741
J Antimicrob Chemother

Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]

2026 Jun 3;81(7):dkag204. PMID: 42267541
J Antimicrob Chemother

In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]

2020 Jul 1;75(7):1850-1858. PMID: 32154866
Microb Pathog

Bacitracin-resistant Staphylococcus aureus induced in chicken gut and in vitro under bacitracin exposure. [Abstract]

2024 Jun:191:106666. PMID: 38685360
Appl Biochem Biotechnol

Evaluation of Benzothiazole-Chalcone Hybrids: Apoptosis Induction, Docking Analysis, and Anticancer Potential in Gastric Cancer Cells. [Abstract]

2025 Aug 23. PMID: 40848211
Eur J Clin Microbiol Infect Dis

Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]

2025 Sep 29. PMID: 41023358
Water

2025 Jun 6.
Infect Drug Resist

2026 May 8;19.
Infect Drug Resist

In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]

2025 Oct 4:18:5239-5247. PMID: 41069760
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428
Anim Dis

Pasteurella multocida capsular: lipopolysaccharide types D:L6 and A:L3 remain to be the main epidemic genotypes of pigs in China. [Abstract]

2021;1(1):26. PMID: 34778886
J Microbiol Methods

Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa. [Abstract]

2026 Feb 25:107441. PMID: 41759663
Diagn Microbiol Infect Dis

A rapid bacterial labeling method for phenotypic antimicrobial susceptibility testing. [Abstract]

2026 Feb;114(2):117181. PMID: 41205476
bioRxiv

2026 Jan 19.
Orebro University

2024.
bioRxiv

2024 Nov 06.
bioRxiv

2024 May 10.
bioRxiv

2024 Feb 9.
bioRxiv

2024 Jan 18.
Research Square Preprint

2020 Jun.
Patent

US20200101105A1.

Solvent & Solubility

In Vitro:

0.1 M HCl : 16.67 mg/mL (50.31 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

H₂O : 5.65 mg/mL (17.05 mM; ultrasonic and adjust pH to 2 with 1 M HCl)

DMSO : 4.86 mg/mL (14.67 mM; ultrasonic and warming and adjust pH to 5 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0180 mL

15.0902 mL

30.1805 mL

5 mM

0.6036 mL

3.0180 mL

6.0361 mL

10 mM

0.3018 mL

1.5090 mL

3.0180 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63. [Content Brief]

[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16. [Content Brief]

[3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O / 0.1 M HCl	1 mM	3.0180 mL	15.0902 mL	30.1805 mL	75.4512 mL
	5 mM	0.6036 mL	3.0180 mL	6.0361 mL	15.0902 mL
	10 mM	0.3018 mL	1.5090 mL	3.0180 mL	7.5451 mL
H₂O / 0.1 M HCl	15 mM	0.2012 mL	1.0060 mL	2.0120 mL	5.0301 mL
0.1 M HCl	20 mM	0.1509 mL	0.7545 mL	1.5090 mL	3.7726 mL
	25 mM	0.1207 mL	0.6036 mL	1.2072 mL	3.0180 mL
	30 mM	0.1006 mL	0.5030 mL	1.0060 mL	2.5150 mL
	40 mM	0.0755 mL	0.3773 mL	0.7545 mL	1.8863 mL
	50 mM	0.0604 mL	0.3018 mL	0.6036 mL	1.5090 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ciprofloxacin

57 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ciprofloxacin

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ciprofloxacin

All Topoisomerase Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (57)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ciprofloxacin

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ciprofloxacin

All Topoisomerase Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (57)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ciprofloxacin Related Classifications

HY-B0356 Related Classifications